ArticleRheumatology international2013
Hesperidin inhibits collagen-induced arthritis possibly through suppression of free radical load and reduction in neutrophil activation and infiltration.
Article in Rheumatology international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Efficacy and safety of dietary polyphenols in rheumatoid arthritis: A systematic review and meta-analysis of 47 randomized controlled trials.Frontiers in immunology · 2023Pooled it
- Hesperidin: a bioflavonoid with broad therapeutic promise.Inflammopharmacology · 2026Review
- Hesperidin: A Multifunctional Flavonoid with Therapeutic Potential in the Management of Pathogenesis.International journal of molecular sciences · 2026Review
- Review
- A Comprehensive Review on Plant Bioactive Compounds-based Novel Drug Delivery System for the Treatment of Rheumatoid Arthritis.Pharmaceutical nanotechnology · 2026Review
- In Vitro and In Silico Studies on Unique Key Components of Hypericum Species, Focusing on Their Role in Inhibiting Enzymatic Pathways.Chemistry & biodiversity · 2026Article
- Phytochemicals and nanoformulation strategies for rheumatoid arthritis: mechanistic insights, therapeutic advances, and translational challenges.Inflammopharmacology · 2026Review
- Flavonoids and flavonoid-based nanoparticles for the treatment of arthritis.Inflammopharmacology · 2025Review
- Novel antiarthritic mechanisms of Azelaic acid against CFA-induced arthritis in rats by modulating pro- and anti-inflammatory cytokines network.Inflammopharmacology · 2024Article
- Mesenchymal Stem Cells-Involved Strategies for Rheumatoid Arthritis Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Review
- Targeting dysregulated intracellular immunometabolism within synovial microenvironment in rheumatoid arthritis with natural products.Frontiers in pharmacology · 2024Review
- Therapeutic Effects of Citrus Flavonoids Neohesperidin, Hesperidin and Its Aglycone, Hesperetin on Bone Health.Biomolecules · 2022Review
- Compatibility ofBioengineered · 2022Article
- Micronutrients: Essential Treatment for Inflammatory Arthritis?Current rheumatology reports · 2020Review
- Appraisal of disease-modifying potential of amlodipine as an anti-arthritic agent: new indication for an old drug.Inflammopharmacology · 2020Article
- Food-Derived Nanoscopic Drug Delivery Systems for Treatment of Rheumatoid Arthritis.Molecules (Basel, Switzerland) · 2020Review
- Immunomodulating action of the 3-phenylcoumarin derivative 6,7-dihydroxy-3-[3',4'-methylenedioxyphenyl]-coumarin in neutrophils from patients with rheumatoid arthritis and in rats with acute joint inflammation.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2020Article
- Could Polyphenols Help in the Control of Rheumatoid Arthritis?Molecules (Basel, Switzerland) · 2019Review
- The association of CAT-262C/T polymorphism with catalase activity and treatment response in juvenile idiopathic arthritis.Rheumatology international · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis is a chronic inflammatory disease characterized by the destruction of articular cartilage and bone in a chronic phase. Pathology of rheumatoid arthritis suggests autoimmunity linked to inflammation. In our study, rheumatoid arthritis was induced in Wistar rats by intradermal injections of 100 μl of emulsion containing bovine type II collagen in complete Freund's adjuvant at the base of the tail. Disease developed about 13 ± 1 days after immunization and treatment with hesperidin (HES) at a dose of 160 mg kg(-1) body weight was given after onset of disease daily until 20th day. The effect of treatment in the rats was monitored by clinical scoring, biochemical parameters and histological evaluations in joints. A steady increase in the articular elastase, nitric oxide and lipid peroxidation was observed in joints of arthritic rats as compared to control, whereas a significant decrease in reduced glutathione, superoxide dismutase activity and catalase was observed in collagen-induced arthritis rats as compared to control group. The results from the present work indicate that the treatment with hesperidin was effective in bringing about significant changes on all the parameters studied in collagen-induced arthritis rats. These data confirm that erosive destruction of the joint cartilage in collagen-induced arthritis is due free radicals released by activated neutrophils and produced by other biochemical pathways. In the present study, an attempt has been made to amelioration of the disease process by a natural product. These results suggest that oral administration of HES could be effective for treating human RA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.